Eduardo Díaz‐Rubio

22.9k total citations · 4 hit papers
351 papers, 12.0k citations indexed

About

Eduardo Díaz‐Rubio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Eduardo Díaz‐Rubio has authored 351 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Oncology, 103 papers in Pulmonary and Respiratory Medicine and 80 papers in Pathology and Forensic Medicine. Recurrent topics in Eduardo Díaz‐Rubio's work include Colorectal Cancer Treatments and Studies (146 papers), Cancer Treatment and Pharmacology (88 papers) and Genetic factors in colorectal cancer (65 papers). Eduardo Díaz‐Rubio is often cited by papers focused on Colorectal Cancer Treatments and Studies (146 papers), Cancer Treatment and Pharmacology (88 papers) and Genetic factors in colorectal cancer (65 papers). Eduardo Díaz‐Rubio collaborates with scholars based in Spain, United States and France. Eduardo Díaz‐Rubio's co-authors include Arié Figer, Jim Cassidy, Werner Scheithauer, Leonard B. Saltz, Fernando Rivera, Stephen Clarke, Sheryl Koski, Javier Sastre, Tsai‐Shen Yang and Mikhail Lichinitser and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Eduardo Díaz‐Rubio

340 papers receiving 11.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 734 citations Eduardo Díaz‐Rubio et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

2016 434 citations Leonard B. Saltz, Eduardo Díaz‐Rubio et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eduardo Díaz‐Rubio Spain	49	8.7k	3.5k	2.4k	2.0k	2.0k	351	12.0k
Howard S. Höchster United States	56	8.1k 0.9×	3.3k 0.9×	1.8k 0.8×	2.4k 1.2×	1.8k 0.9×	342	12.0k
H. Cortés-Funes Spain	44	6.4k 0.7×	2.6k 0.8×	2.1k 0.9×	1.8k 0.9×	1.3k 0.7×	192	9.6k
John Primrose United Kingdom	56	7.0k 0.8×	3.2k 0.9×	5.0k 2.1×	2.0k 1.0×	1.8k 0.9×	230	12.8k
Joseph P. Eder United States	47	8.2k 1.0×	3.2k 0.9×	1.6k 0.7×	3.4k 1.7×	1.6k 0.8×	178	12.2k
Fausto Petrelli Italy	50	5.9k 0.7×	3.2k 0.9×	2.3k 1.0×	1.3k 0.7×	1.7k 0.8×	280	9.1k
Takashi Aikou Japan	59	5.2k 0.6×	4.3k 1.2×	4.6k 2.0×	3.5k 1.7×	1.7k 0.9×	400	12.5k
Niall C. Tebbutt Australia	48	9.3k 1.1×	4.4k 1.2×	3.0k 1.3×	2.7k 1.3×	2.0k 1.0×	255	12.8k
Lee S. Rosen United States	50	8.4k 1.0×	3.8k 1.1×	1.8k 0.7×	3.6k 1.8×	1.1k 0.5×	232	12.1k
Patrick Schöffski Belgium	68	9.6k 1.1×	9.5k 2.7×	3.2k 1.4×	4.8k 2.4×	2.2k 1.1×	510	19.4k
Tamas Hickish United Kingdom	45	10.2k 1.2×	4.3k 1.2×	3.1k 1.3×	1.6k 0.8×	1.9k 1.0×	145	13.5k

Countries citing papers authored by Eduardo Díaz‐Rubio

Since Specialization

Citations

This map shows the geographic impact of Eduardo Díaz‐Rubio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo Díaz‐Rubio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo Díaz‐Rubio more than expected).

Fields of papers citing papers by Eduardo Díaz‐Rubio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo Díaz‐Rubio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo Díaz‐Rubio. The network helps show where Eduardo Díaz‐Rubio may publish in the future.

Co-authorship network of co-authors of Eduardo Díaz‐Rubio

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo Díaz‐Rubio. A scholar is included among the top collaborators of Eduardo Díaz‐Rubio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo Díaz‐Rubio. Eduardo Díaz‐Rubio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raimondi, Alessandra, Federico Nichetti, Arndt Stahler, et al.. (2023). Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. European Journal of Cancer. 190. 112945–112945. 7 indexed citations

Benavides, Manuel, Auxiliadora Gómez‐España, Pilar García‐Alfonso, et al.. (2021). Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). European Journal of Surgical Oncology. 48(5). 1123–1132. 3 indexed citations

Carmona‐Rodríguez, Lorena, María Jesús Fernández‐Aceñero, Alicia González-Martín, et al.. (2020). SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells. Journal for ImmunoTherapy of Cancer. 8(1). e000432–e000432. 36 indexed citations

Mira, E., Lorena Carmona‐Rodríguez, Beatriz Pérez‐Villamil, et al.. (2018). SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α. Nature Communications. 9(1). 575–575. 51 indexed citations

Romero, Atocha, Aleix Prat, José Á. García-Sáenz, et al.. (2013). Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection. Clinical & Translational Oncology. 16(4). 386–394. 19 indexed citations

Sastre, Javier, Marta Vidaurreta, Fernando Rivera, et al.. (2013). Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer. 12(4). 280–286. 30 indexed citations

Romero, Atocha, Trinidad Caldés, Eduardo Díaz‐Rubio, & Miguel Martín. (2012). Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. Clinical & Translational Oncology. 14(3). 163–168. 22 indexed citations

Zugazagoitia, Jon, Aránzazu Manzano, Javier Sastre, et al.. (2012). Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clinical & Translational Oncology. 15(2). 146–153. 13 indexed citations

Romero, Atocha, Miguel Martín, Maggie C.U. Cheang, et al.. (2011). Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization. American Journal Of Pathology. 178(4). 1453–1460. 57 indexed citations

10.

Garré, Pilar, Rosa M. Xicola, Brian J. Doyle, et al.. (2011). Analysis of the Oxidative Damage Repair Genes NUDT1 , OGG1 , and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC). Clinical Cancer Research. 17(7). 1701–1712. 28 indexed citations

11.

Puente, Javier, Sara López‐Tarruella, Amparo Ruı́z, et al.. (2010). Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Research and Treatment. 122(2). 591–600. 36 indexed citations

12.

Saltz, Leonard B., Stephen Clarke, Eduardo Díaz‐Rubio, et al.. (2008). Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology. 26(12). 2013–2019. 2275 indexed citations breakdown →

13.

López, Norberto Batista, et al.. (2006). Oncologists’ perceptions of cancer pain management in Spain: The real and the ideal. European Journal of Pain. 11(3). 352–359. 13 indexed citations

14.

González-Larriba, J.L., et al.. (2006). Cáncer de pulmón. 631(631). 11–22. 20 indexed citations

15.

Abad, Albert, Alfredo Carrato, Matilde Navarro, et al.. (2005). Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 4(6). 384–389. 7 indexed citations

16.

Hoya, Miguel de la, Hanne Meijers‐Heijboer, Juan Manuel Fernández, et al.. (2004). Mutant BRCA1 alleles transmission: Different approaches and different biases. International Journal of Cancer. 113(1). 166–167.

17.

Hoya, Miguel de la, Ana Osório, Alicia Tosar, et al.. (2001). Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing. International Journal of Cancer. 97(4). 466–471. 62 indexed citations

18.

Díaz‐Rubio, Eduardo, et al.. (1990). Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone. Annals of Oncology. 1(5). 379–380. 3 indexed citations

19.

Díaz‐Rubio, Eduardo, et al.. (1990). Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. European Journal of Cancer and Clinical Oncology. 26(6). 727–729. 34 indexed citations

20.

Martín, Miguel, et al.. (1989). Lethal Cardiac Toxicity after Cisplatin and 5-Fluorouracil Chemotherapy. American Journal of Clinical Oncology. 12(3). 229–234. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact